Phaseline

Companies › RiboX Therapeutics

RiboX Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RXRG001
Circular RNA encoding human aquaporin 1 delivered via lipid nanoparticle
AQP1Phase 1Radiation-Induced Xerostomia and HyposalivationAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06714253RXRG001Phase 1Radiation-Induced Xerostomia and HyposalivationGastroenterologyAug 2027

Targets

AQP1 (1)

Companies with the same targets

MeiraGTx

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.